ArticleClinical rheumatology2026
Development of the treatment adherence scale for rheumatic diseases.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Amyloidosis awareness and colchicine adherence in patients with familial Mediterranean fever: a cross-sectional study in an endemic region.Clinical rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION/
objectivesThis study aims to develop a new scale to measure treatment adherence in rheumatic diseases and to measure participants' attitudes towards treatment adherence.
methodThe data were obtained using the "treatment adherence scale for rheumatic diseases," which was developed to measure treatment adherence in rheumatic conditions. The research sample comprised 402 patients, and demographic variables were collected. During the scale development process, the Pearson correlation coefficient, Bartlett's test, the Kaiser-Meyer-Olkin value, and exploratory and confirmatory factor analysis methods were used. In confirmatory factor analysis, the validity of the model was evaluated using root mean square error of approximation, non-normed fit index/Tucker-Lewis indices, comparative fit index, normed fit index, and chi-square goodness-of-fit test. In reliability analyses, composite reliability and Cronbach's alpha coefficient were calculated. For descriptive analyses, frequency distributions, measures of dispersion and central tendency, and multiple linear regression analyses were employed.
resultsFindings related to the scale development phase: The developed "treatment adherence scale for rheumatic diseases" consists of four factors: behavioral adherence to the treatment process, collaboration and communication with healthcare professionals, medication awareness and consciousness, and medication treatment commitment. The scale comprises 20 items and is scored on a Likert scale. The scale's reliability was 0.92, explaining 55.7% of the total variance. According to confirmatory factor analysis results, the fit indices were found to be χ
conclusionsThe findings reveal that the researchers' treatment adherence scale for rheumatic diseases is a reliable and valid assessment instrument. Using this scale may enhance patient care and treatment management in rheumatic disorders. Furthermore, understanding characteristics that influence treatment adherence might improve treatment efficacy and help lower the total societal burden. Key Points • This study reveals that a newly developed scale for assessing treatment adherence in rheumatic patients is valid and reliable. • The scale offers a thorough assessment by examining patients'' treatment approaches from multiple perspectives, including behavioral, communicative, and drug awareness. • Age and particular individual factors can influence treatment adherence; therefore, customized encouragement and interventions are important..
Indexed as
Identifiers
41417175What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.